Gsa Capital Partners LLP Protalix Bio Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 209,292 shares of PLX stock, worth $303,473. This represents 0.05% of its overall portfolio holdings.
Number of Shares
209,292
Previous 305,749
31.55%
Holding current value
$303,473
Previous $575,000
6.78%
% of portfolio
0.05%
Previous 0.04%
Shares
12 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.72 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.4 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.25 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$992,8990.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$891,8730.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $72.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...